secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beam Therapeutics Inc. (BEAM)
CIK:        0001745999
Form:       8-K
Filed at:   2022-09-07T23:59:59+00:00
Accession:  0000950170-22-018147
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Beam Therapeutics enters license collaboration with Orbital; will consolidate it financially
--------------------------------------------------------------------------------

- Beam receives 75M shares of Orbital common stock; expects to consolidate Orbital under ASC 810.
- Cross-licenses for non-viral delivery and RNA design; exclusive fields for each party run three years.
- Beam's Giuseppe Ciaramella becomes Orbital interim CEO; other Beam executives take interim leadership roles.
- Three Beam directors (Burow, Evans, Maraganore) join Orbital board; ARCH Venture Partners holds Orbital stock.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1745999/000095017022018147/0000950170-22-018147-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1745999/000095017022018147/beam-20220902.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-018147

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer